No Data
No Data
Cerevel Therapeutics Holdings(CERE.US) Director Sells US$2.11 Million in Common Stock
$Cerevel Therapeutics Holdings(CERE.US)$ Director COLES N ANTHONY sold 50,000 shares of common stock on May 10, 2024 at an average price of $42.1025 for a total value of $2.11 million.Source: Announce
Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing
N Anthony Coles, Director, on May 10, 2024, sold 50,000 shares in Cerevel Therapeutics Holdings (CERE) for $2,105,125. Following the Form 4 filing with the SEC, Coles has control over a total of 15,63
Form 144 | Cerevel Therapeutics Holdings(CERE.US) Director Proposes to Sell 2.12 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Cerevel Therapeutics Holdings(CERE.US)$ Director NEAVELLE ANTHONY COLES intends to sell 50,000 shares of its common stock on May 10, with a total market value of appro
Cerevel Therapeutics Holdings | 10-Q: Quarterly report
Cerevel Therapeutics Holdings Insiders Placed Bullish Bets Worth US$2.51m
Quite a few insiders have dramatically grown their holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) over the past 12 months. An insider's optimism about the company's prospects is a posit
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study
On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease. The TEMPO-3 trial evaluated the effi